About

IDT – What’s next?

A few weeks back IDT Australia announced that the Australian government had approached the company to conduct a feasibility study into the possibility of producing a COVID-19 vaccine product at it’s Melbourne facility. Though IDT is yet to publicly update the market, it appears the company has completed the study and submitted the result to the government. This comes at a time that the Australian government has been under fire for it’s over promising and Read more…

By Ratfink, ago

IDT Australia

  IDT Australia – Showing signs of life? After well over a decade in the wilderness, IDT Australia may just be beginning to show signs of life.   The GFC sent a wrecking ball through IDT’s business at around the same time that company management failed to see the shifting sands of globalization driving production of their core products offshore.  Humble beginnings Although IDT is virtually unknown to Australian investors, the company’s story stretches back Read more…

By Ratfink, ago

MSB update – March 2021

  Mesoblast update As usual, there’s plenty to think about for shareholders of Aussie biotech hopeful, Mesoblast.  But before we kick off, if you are not familiar with the company’s recent history, these previous blog posts will bring you up to date:  https://undiscoveredbiotech.com/2020/11/20/novartis-partnership/ https://undiscoveredbiotech.com/2020/12/22/mesoblasted/ https://undiscoveredbiotech.com/2021/01/23/novartis-or-bust/ Moving right along… CLBP After an agonizing series of delays, Mesoblast released some of the headline results from its 400-patient phase 3 trial into chronic lower back pain (CLBP). Taking Read more…

By Ratfink, ago

Novartis or bust?

    After an ugly few months for Australian biotech, Mesoblast, intrigue is building during what may become pivotal 6 weeks.  CLBP Most followers will be aware that top line results of the company’s phase 3 trial into chronic lower back pain (CLBP) is well overdue. The original date for the release of the data was slated for “mid-year”. For clarification, that was supposed to be mid-year 2020, not 2021.  Repeated delays in this trial Read more…

By Ratfink, ago

Happy New Year?

  Happy New Year? January looms as a crucial month for the near-term prospects of Australian biotech, Mesoblast.  December saw the company’s treatments fail to meet primary endpoints in both its Chronic Heart Failure (CHF) and COVID-19 Acute Respiratory Distress Syndrome (C19 ARDS) phase 3 trials.  These failures, along with an earlier failure to be granted FDA marketing approval for its graft versus host disease treatment (GVHD), has seen the share price tumble.  First Up Read more…

By Ratfink, ago
Mesoblasted

Mesoblasted

  Mesoblasted !  22/12/2020 In a tumultuous few days for biotech hopeful, Mesoblast, a series of poor results has seen the share price smashed down by over 50% in less than a week.  This all came on top an earlier failure by Mesoblast to gain approval for their treatment for pediatric, graft versus host disease (GVHD)    Chronic Heart Failure The week started with the topline results for their DREAM-HF phase 3 trial into chronic Read more…

By Ratfink, ago
Atomo Diagnostics

Atomo Diagnostics

  Atomo Diagnostics ASX code : AT1 It speaks volumes that emerging Australian biotech company, Atomo Diagnostics, chose to list on the ASX during the first Australian lockdown of the 2020 COVID-19 pandemic.  For the Sydney based company, it was possibly the case of being in the right place at the right time, and the market appears to agree with the share price up around 60% ($0.32) in the seven months they’ve been listed.  Background. Read more…

By Ratfink, ago

Investing Mistakes #2

Investing Mistakes #2    In the investing world there are many hidden dangers. Large foreign currency fluctuations, for example, can have massive impact on companies whose product are produced in one country and sold in the currency of another.   A good example of that would be the large Australian mining company, BHP, whose major products are mostly extracted in Australia, but sold in US dollars.  Other hidden dangers are sometimes of our own making. In Read more…

By Ratfink, ago
Novartis

Novartis Partnership

Novartis Partnership  The prospect has taken up countless column inches in various newspapers and web forums over the years but today Mesoblast has finally found itself a tier one pharma company to collaborate on its promising treatment for inflammatory diseases, remestemcel-L.  The Swiss major, Novartis has entered into an exclusive license and collaboration agreement with Mesoblast for the development, manufacture and commercialization of remestemcel-L for the treatment of Acute Respiratory Distress Syndrome (ARDS), including that Read more…

By Ratfink, ago
Bot attack

Bot attack update

As mentioned in an earlier post this site has come under a bot attack recently. To mitigate that I suspended all new registrations to this site and deleted dozens of fraudulent accounts. This is an annoying part of owning a website. The good news is that some measures have been put in place to solve that problem, the most visible of which is adding a reCaptcha to the login and registration pages.  With the new Read more…

By Ratfink, ago